Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in uniQure N.V., BioCryst Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how uniQure N.V., BioCryst Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About uniQure N.V., BioCryst Pharmaceuticals and Inc.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Latest Biotechnology and uniQure N.V., BioCryst Pharmaceuticals, Inc. Stock News

As of July 31, 2026, uniQure N.V. had a $3.0 billion market capitalization, compared to the Biotechnology median of $252.6 million. uniQure N.V.’s stock is up 82.3% in 2026, up 12% in the previous five trading days and up 202.21% in the past year.

Currently, uniQure N.V. does not have a price-earnings ratio. uniQure N.V.’s trailing 12-month revenue is $18.7 million with a % net profit margin. Year-over-year quarterly sales growth most recently was 9.4%. Analysts expect adjusted earnings to reach $-3.877 per share for the current fiscal year. uniQure N.V. does not currently pay a dividend.

As of July 31, 2026, BioCryst Pharmaceuticals, Inc. had a $2.3 billion market cap, putting it in the 56th percentile of all stocks. BioCryst Pharmaceuticals, Inc.’s stock is up 15.1% in 2026, down 3.9% in the previous five trading days and up 9.25% in the past year.

Currently, BioCryst Pharmaceuticals, Inc. does not have a price-earnings ratio. BioCryst Pharmaceuticals, Inc.’s trailing 12-month revenue is $885.7 million with a -51.7% net profit margin. Year-over-year quarterly sales growth most recently was 7.5%. Analysts expect adjusted earnings to reach $0.660 per share for the current fiscal year. BioCryst Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare uniQure N.V., BioCryst Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at uniQure N.V., BioCryst Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

uniQure N.V., BioCryst Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
uniQure N.V.	QURE	F
BioCryst Pharmaceuticals, Inc.	BCRX	B

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

uniQure N.V. has a Value Score of 2, which is Ultra Expensive. BioCryst Pharmaceuticals, Inc. has a Value Score of 62, which is Value.

The Value Stock Winner: BioCryst Pharmaceuticals, Inc.

As you can clearly see from the Value Grade breakdown above, BioCryst Pharmaceuticals, Inc. is considered to have better value than uniQure N.V.. For investors who focus solely on a company’s valuation, BioCryst Pharmaceuticals, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

uniQure N.V., BioCryst Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
uniQure N.V.	QURE	F
BioCryst Pharmaceuticals, Inc.	BCRX	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

uniQure N.V. has a Quality Score of 13, which is Very Weak. BioCryst Pharmaceuticals, Inc. has a Quality Score of 47, which is Average.

The Quality Stock Winner: No Clear Winner

Neither uniQure N.V., BioCryst Pharmaceuticals or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if uniQure N.V., BioCryst Pharmaceuticals or Inc. is the better investment when it comes to quality.

uniQure N.V., BioCryst Pharmaceuticals and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
uniQure N.V.	QURE	F
BioCryst Pharmaceuticals, Inc.	BCRX	A

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

uniQure N.V. has a Earnings Estimate Score of 16, which is Very Negative. BioCryst Pharmaceuticals, Inc. has a Earnings Estimate Score of 81, which is Very Positive.

The Earnings Estimate Revisions Grade Winner: BioCryst Pharmaceuticals, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, BioCryst Pharmaceuticals, Inc. has a better Earnings Estimate Revisions Grade than uniQure N.V.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, BioCryst Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other uniQure N.V., BioCryst Pharmaceuticals and Inc. Grades

In addition to Quality, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether uniQure N.V., BioCryst Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, uniQure N.V., BioCryst Pharmaceuticals or Inc. Stock?

Overall, uniQure N.V. stock has a Value Score of 2, Estimate Revisions Score of 16 and Quality Score of 13.

BioCryst Pharmaceuticals, Inc. stock has a Value Score of 62, Estimate Revisions Score of 81 and Quality Score of 47.

Comparing uniQure N.V., BioCryst Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.